The IL-23-IL-17 Immune Axis: From Mechanisms to Therapeutic Testing

Nat Rev Immunol. 2014 Sep;14(9):585-600. doi: 10.1038/nri3707.

Abstract

Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major revision of the TH subset paradigm and substantial progress has been made in deciphering the molecular mechanisms of T cell lineage commitment and function. In this Review, we focus on the recent advances that have been made regarding the transcriptional control of TH17 cell plasticity and stability, as well as the effector functions of TH17 cells, and we highlight the mechanisms of IL-17 signalling in mesenchymal and barrier epithelial tissues. We also discuss the emerging clinical data showing that IL-17-specific and IL-23-specific antibody treatments are remarkably effective for treating many immune-mediated inflammatory diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antibodies / therapeutic use
  • Autoimmune Diseases / therapy*
  • Cytokines / immunology
  • Epithelial Cells / immunology
  • Humans
  • Interleukin-17 / genetics
  • Interleukin-17 / immunology*
  • Interleukin-23 / genetics
  • Interleukin-23 / immunology*
  • Receptors, Interleukin-17 / immunology
  • Signal Transduction / immunology
  • Th17 Cells / immunology*
  • Tight Junctions / immunology
  • Transcription, Genetic / immunology

Substances

  • Antibodies
  • Cytokines
  • IL17RA protein, human
  • Interleukin-17
  • Interleukin-23
  • Receptors, Interleukin-17